Einar Pontén, CEO of Lipum, and Professor Anders Fasth.
Einar Pontén, CEO of Lipum, and Professor Anders Fasth.

Pressmeddelande -

Expert advisor enters Lipum

Now Umeå company Lipum brings more expertise to the company. Professor Anders Fasth steps in as an advisor in the development of medicines for inflammatory diseases.

“It is very gratifying that he joins the team,” says Einar Pontén, CEO of Lipum.

Lipum has developed a biological drug candidate for the treatment of chronic inflammatory diseases and aim for a better treatment of juvenile idiopathic arthritis (JIA), that affects children. Therefore, the scientific advisory board of the company is now strengthened with Anders Fasth, senior professor of pediatric immunology at the University of Gothenburg and a senior consultant at Queen Silvia Children’s Hospital in Gothenburg, Sweden.

“I started treating children with rheumatism several decades ago. We today have effective medicines to choose from, but still many children have an insufficient response. Therefore, it feels very stimulating to be closely involved in an exciting development concerning the treatment of inflammatory diseases and especially in children,” says Anders Fasth.

Pre-clinical studies have shown very promising results and a unique mechanism of action that has the potential to provide better treatment of chronic inflammatory diseases. The lead candidate drug SOL-116 is a fully-humanized monoclonal antibody. It is in production development and toxicological studies will be conducted during next year and clinical trials will be initiated during 2021.

“Our scientific advisory board is very committed and competent. In addition to ongoing contacts, we also gather for an annual workshop where current issues and the future are discussed. Anders has already been contributing during these and it is very gratifying that he now also joins the team. The scientific advisory board is an important resource for Lipum and the other members are professor Rikard Holmdahl, Dr Björn Löwenadler and professor Solbritt Rantapää Dahlqvist”, says CEO Einar Pontén.

About Lipum AB

Lipum is a biopharmaceutical company focused on chronic inflammatory diseases. The company has identified a novel protein as target molecule and is therefore developing new biological drugs for blocking the protein as treatment. The company is located in the Umeå Biotech Incubator in Umeå, Sweden. The company has support from European Commission program Horizon 2020.

For more information, please contact:

Einar Pontén, CEO
einar.ponten@lipum.se
+46 70-5783495

Relaterade länkar

Ämnen

Kategorier

Regioner

Umeå Biotech Incubator (UBI) is one of Sweden’s state-of-the-art business incubators within the life sciences. We help researchers to use their data to the benefit of patients and citizens, improving their health. We support and train entrepreneurs in the fields of pharmaceuticals, diagnostics and medical engineering, and act as a bridge between academia, medicine and the business community.

Kontakter

Tomas Ruuth

Tomas Ruuth

Presskontakt Kommunikationsansvarig PR & Communications 072-4024697 www.ubi.se

Relaterad media Ladda ner bilder för medieanvändning

Einar Pontén, CEO of Lipum, and Professor Anders Fasth
  • Einar Pontén, CEO of Lipum, and Professor Anders Fasth
  • Licens: Medieanvändning
    Innehållet får laddas ner, användas och delas i olika mediekanaler av t.ex. journalister, bloggare, krönikörer, opinionsbildare etc., i syftet att förmedla, redogöra för och kommentera ert pressmeddelande, inlägg eller information, så länge innehållet används oförändrat och i dess helhet. Upphovsmannen ska anges i den omfattning och på det sätt god sed kräver (vilket bl.a. innebär att fotografer till bilder nästan alltid måste anges).
  • Av: Press
  • Filformat: .jpg
  • Storlek: 1914 x 1200, 1,69 MB
Ladda ner

Relaterat innehåll

Umeå life science company attends world congress - “Our product has huge potential”

Umeå life science company attends world congress - “Our product has huge potential”

Umeå life science company Lipum will participate in one of the world's largest congresses for rheumatic diseases this June. “The elite of our industry gathers at this congress once a year and competition is incredibly intense. It’s important to be seen there”, says Einar Pontén, CEO of Lipum.

Pernilla Abrahamsson, new COO at Lipum.

Life science profile swaps stock market for startup

Life science industry figurehead Pernilla Abrahamsson has left her position as Product Development Manager at stock market listed Senzime to become Chief Operating Officer (COO) at Lipum, located at the Umeå Biotech Incubator. Pernilla Abrahamsson had previously developed the OnZurf Probe at her own company MD Biomedical.

Dr Kristian Sandberg, Director of the Drug Discovery and Development platform at SciLifeLab.

Biotech Expert Joins Lipum Board

Dr Kristian Sandberg, Director of the Drug Discovery and Development platform at SciLifeLab, has joined the board of Umeå-based biotech company Lipum. “Kristian has extensive experience in drug development. We are absolutely delighted to announce his appointment”, says Ulf Björklund, Chairman of the Board at Lipum.

Marina Norberg, CFO Lipum.

Marina Norberg new CFO at Lipum AB

Lipum AB has appointed Marina Norberg Chief Financial Officer (CFO).

Lipum.

Lipum raises SEK 85 million and become listed on Nasdaq First North

Umeå-based biopharmaceutical company Lipum has been working towards a stock exchange listing since 2018 – and now the moment has finally arrived. On Thursday, April 22, shares in Lipum will be traded on the Nasdaq First North Growth Market for the very first time. The company will ring Nasdaq's opening bell, which has been specially transported to Umeå, to mark the occasion.

We grow ideas that can change the world

Umeå Biotech Incubator (UBI) is one of Sweden’s state-of-the-art business incubators within the life sciences. We help researchers to use their data to the benefit of patients and citizens, improving their health. We support and train entrepreneurs in the fields of pharmaceuticals, diagnostics and medical engineering, and act as a bridge between academia, medicine and the business community.

Umeå Biotech Incubator
Tvistevägen 48C
907 36 Umeå
Sverige
ubi.se